ILEX Oncology Inc

Registration country: 
United States
ISIC Code: 
ILEX Oncology, Inc. engages in the development and commercialization of therapeutic treatments, primarily in oncology. Its lead product is marketed as CAMPATH in the United States and as MABCAMPATH in Europe and other countries for the treatment of patients with B-cell chronic lymphocytic leukemia, a type of blood cancer characterized by progressive accumulation of B-lymphocytes.